OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Conditions:   Breast Cancer;   Advanced Breast Cancer;   Metastatic Breast Cancer;   ER Positive Breast Cancer;   HER2 Negative Breast Carcinoma Interventions:   Drug: OP-1250;   Drug: Fulvestrant;   Drug: Anastrozole;   Drug: Letrozole;   Drug: Exemestane Sponsor:   Olema Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials